If someone received one dose of Shingrix (recombinant zoster vaccine) 2 years ago, do they need to repeat the whole series?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Shingrix Vaccination After Incomplete Series

If someone received only one dose of Shingrix (recombinant zoster vaccine) 2 years ago, they should receive the second dose as soon as possible to complete the series without restarting the entire series. 1, 2

Rationale for Completing the Series

The Advisory Committee on Immunization Practices (ACIP) and CDC guidelines clearly indicate that:

  • The standard Shingrix vaccination schedule consists of two doses (0.5 mL each) administered 2-6 months apart 2
  • There is no maximum interval between doses - if the second dose is delayed, it should still be administered as soon as possible without restarting the series 1
  • Completing the full two-dose series is crucial for optimal protection 2, 3

Effectiveness of Complete vs. Incomplete Series

Real-world effectiveness data strongly supports completing the series:

  • Two-dose effectiveness: 70.1% (95% CI, 68.6-71.5) 3
  • One-dose effectiveness: 56.9% (95% CI, 55.0-58.8) 3

This significant difference in effectiveness (approximately 13% higher with two doses) underscores the importance of completing the full series, even when the second dose is delayed beyond the recommended 2-6 month interval.

Administration Guidelines

When administering the delayed second dose:

  • No need to restart the series regardless of the time elapsed since the first dose 1
  • Administer the second dose subcutaneously in the deltoid region 2
  • The vaccine can be given simultaneously with other vaccines if needed (such as influenza or pneumococcal vaccines) 2

Special Considerations

Immunocompromised Patients

  • For immunocompromised adults, a shortened dosing interval of 1-2 months between doses is recommended 2
  • Even with delayed administration, the second dose remains effective in immunocompromised individuals 2

Previous Zoster Episode

  • Having had a previous episode of herpes zoster is not a contraindication to completing the Shingrix series 1, 2
  • In fact, vaccination is recommended to prevent future episodes once the acute episode has completely resolved 2

Common Pitfalls to Avoid

  1. Restarting the series unnecessarily: There is no maximum interval after which the series must be restarted - simply administer the second dose as soon as possible 1

  2. Assuming one dose provides sufficient protection: While one dose provides some protection (56.9% effectiveness), completing the series significantly improves effectiveness to 70.1% 3

  3. Delaying the second dose indefinitely: Although there's no maximum interval, unnecessary delay should be avoided as the patient remains suboptimally protected until the series is completed 2

  4. Confusing recommendations between Shingrix and the older Zostavax vaccine: Unlike the older live zoster vaccine (Zostavax), Shingrix requires two doses for optimal effectiveness 2, 4

In conclusion, for someone who received one dose of Shingrix 2 years ago, the clear recommendation is to administer the second dose as soon as possible without restarting the series, regardless of the extended interval since the first dose.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Shingrix Vaccination Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021

Research

Herpes Zoster Vaccines.

The Journal of infectious diseases, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.